Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Il punto su

PDF MeBrain

Fidarsi o non fidarsi del test prenatale non invasivo. Riflessioni a partire da un caso di falso negativo

To trust or not to trust non-invasive prenatal testing? A case of false negative

Alessandro Neirotti1,2, Sabrina Bombaci1, Carlotta Rubino1
1Università di Torino, Italia
2SC Pediatria, AOU “SS Antonio e Biagio e Cesare Arrigo”, Alessandria, Italia

Novembre 2024 | DOI: 10.53126/MEBXXVIIN183

Abstract
Non-invasive prenatal testing (NIPT) is a screening for foetal chromosomal abnormalities that identifies at-risk pregnancies and is used to propose a possible invasive genetic confirmation testing in case of its positive results. For Down syndrome (trisomy 21), its accuracy is close to 100%, while for other investigated conditions, it presents various limitations. In a neonate who presented with severe hypotonia and syndromic features, the NIPT was negative for all the screened anomalies. However, among the various investigations performed for the diagnosis, there was an altered methylation of the chromosomal region 15q11.2, indicative of Prader-Willi syndrome (PWS), previously excluded by NIPT. The paper therefore questions the significance of the results of this investigation in front of a clinical suspicion and reviews the use of NIPT in clinical practice.
Riassunto
Il test prenatale non invasivo (NIPT) è uno screening per le anomalie cromosomiche fetali che individua le gravidanze a rischio, per eventualmente proporre - in caso di risultati positivi - l’indagine genetica invasiva di conferma. Per la sindrome di Down (trisomia 21) mostra un’accuratezza prossima al 100%, mentre per le altre patologie indagate presenta diverse limitazioni. In un neonato giunto alla nostra attenzione per ipotonia severa e tratti sindromici, emerge il dato di un NIPT negativo per tutte le anomalie ricercate. Tuttavia, tra le varie indagini avviate per arrivare alla diagnosi, risulta un’alterata metilazione della regione cromosomica 15q11.2, indicativa di sindrome di Prader-Willi (PWS), precedentemente esclusa al NIPT. Ci siamo quindi domandati che peso dare agli esiti di questa indagine di fronte a un sospetto diagnostico e abbiamo effettuato una revisione narrativa sull’utilizzo del NIPT nella pratica clinica.
Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. Harraway J. Non-invasive prenatal testing. Aust Fam Physician. 2017;46(10):735-9.
  2. Lo KK, Karampetsou E, Boustred C, et al. Limited Clinical Utility of Non-invasive Prenatal Testing for Subchromosomal Abnormalities. Am J Hum Genet. 2016;98(1):34-44. DOI: 10.1016/j.ajhg.2015.11.016.
  3. Hu H, Wang L, Wu J, et al. Noninvasive prenatal testing for chromosome aneuploidies and sub-chromosomal microdeletions/microduplications in a cohort of 8.141 single pregnancies. Hum Genomics. 2019;13(1):14. DOI: 10.1186/s40246-019-0198-2.
  4. Taylor-Phillips S, Freeman K, Geppert J, et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open. 2016;6(1):e010002. DOI: 10.1136/bmjopen-2015-010002.
  5. Ge Y, Li J, Zhuang J, et al. Expanded noninvasive prenatal testing for fetal aneuploidy and copy number variations and parental willingness for invasive diagnosis in a cohort of 18.516 cases. BMC Med Genomics. 2021;14(1):106. DOI: 10.1186/s12920-021-00955-6.
  6. Soukkhaphone B, Lindsay C, Langlois S, Little J, Rousseau F, Reinharz D. Non-invasive prenatal testing for the prenatal screening of sex chromosome aneuploidies: A systematic review and meta-analysis of diagnostic test accuracy studies. Mol Genet Genomic Med. 2021;9(5):e1654. DOI: 10.1002/mgg3.1654.
  7. Chen Y, Lu L, Zhang Y, et al. Clinical application of expanded noninvasive prenatal testing for fetal chromosome abnormalities in a cohort of 39.580 pregnancies. Am J Med Genet A. 2022;188(5):1426-34. DOI: 10.1002/ajmg.a.62657.
  8. Martin K, Iyengar S, Kalyan A, et al. Clinical experience with a single-nucleotide polymorphism-based non-invasive prenatal test for five clinically significant microdeletions. Clin Genet. 2018;93(2):293-300. DOI: 10.1111/cge.13098.
  9. Xue H, Yu A, Lin M, et al. Efficiency of expanded noninvasive prenatal testing in the detection of fetal subchromosomal microdeletion and microduplication in a cohort of 31.256 single pregnancies. Sci Rep. 2022;12(1):19750. DOI: 10.1038/s41598-022-24337-9.
  10. Yang L, Bu G, Ma Y, Zhao J, Rezak J, La X. Comparison of noninvasive prenatal screening for defined pathogenic microdeletion / microduplication syndromes and nonsyndromic copy number variations: a large multicenter study. J Comp Eff Res. 2022;11(17):1277-91. DOI: 10.2217/cer-2022-0088.
  11. Zaninović L, Bašković M, Ježek D, Katušić Bojanac A. Validity and Utility of Non-Invasive Prenatal Testing for Copy Number Variations and Microdeletions: A Systematic Review. J Clin Med. 2022;11(12):3350. DOI: 10.3390/jcm11123350.
  12. Yaron Y, Jani J, Schmid M, Oepkes D. Current Status of Testing for Microdeletion Syndromes and Rare Autosomal Trisomies Using Cell-Free DNA Technology. Obstet Gynecol. 2015;126(5):1095-9. DOI: 10.1097/AOG.0000000000001091.
  13. Butler MG. Benefits and limitations of prenatal screening for Prader-Willi syndrome. Prenat Diagn. 2017;37(1):81-94. DOI: 10.1002/pd.4914